HIMS), the maker of prescription compound drugs that has amassed a popular following from its personalized pill prescriptions ...

If you’re looking to prevent hair loss or stop the progression of any hair loss that’s started, a topical product can help.

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims stock jumped late Monday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

Shares of Hims & Hers (NYSE:HIMS) fell 14% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer considered to be in short supply in the U.S. Certain doses of ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...